UPDATE : Monday, September 7, 2020
상단여백
CHA Biotech revises separate operating profit to a loss in 2018
CHA Biotech announced Thursday that the company revised its separate operat...
by Jeong Sae-im  |  2019-03-15 16:26
라인
'OliX to target global market with RNA technology'
OliX Pharmaceutical’s RNAi (RNA interference) technology is getting the not...
by Lee Han-soo  |  2019-03-15 11:44
라인
Loss-making Medipost seeks to avoid administrative issue designation
Medipost, a company specializing in stem cell research, is drawing the indu...
by Jeong Sae-im  |  2019-03-14 14:33
라인
Celltrion Healthcare wins biosimilar bids in SE Asia
Celltrion Healthcare said that it won the bids for Singapore’s infliximab b...
by Lee Han-soo  |  2019-03-07 14:25
라인
Biogen seeks gene therapy pipeline for rare eye disease
The biotech industry is paying attention to whether Biogen’s recent acquisi...
by Kim Yun-mi  |  2019-03-06 14:41
라인
Europe OKs Samsung Bioepis’ biosimilar treatment of breast cancer
Samsung Bioepis said Tuesday that the European Medicines Agency has granted...
by Lee Han-soo  |  2019-03-05 17:53
라인
Bridge Biotherapeutics to accelerate global presence
Lee Jung-kue, CEO of Bridge Biotherapeutics, is making noticeable strides i...
by Lee Han-soo  |  2019-03-04 10:50
라인
BioGenetics inks deal to supply biliary tract cancer drug in Korea
BioGenetics said it has signed a deal with Singapore-based drugmaker Aslan ...
by Lee Hye-seon  |  2019-02-28 16:49
라인
Researchers find biomarker to predict recurrence of chronic myeloid leukemia
Korean researchers said they have discovered a biomarker to predict a thera...
by Park Gi-taek  |  2019-02-25 16:03
라인
Celltrion Healthcare posts ₩713.5 billion in 2018 sales
Celltrion Healthcare, a subsidiary of Celltrion, said Friday that it record...
by Lee Han-soo  |  2019-02-22 17:29
라인
Alteogen applies for P1 trial for Eylea biosimilar
Alteogen said Friday that it has filed an investigational new drug applicat...
by Lee Han-soo  |  2019-02-22 16:03
라인
Samsung Bioepis, C-Bridge Capital to develop biosimilars in China
Samsung Bioepis said Monday that it has signed a licensing agreement with C...
by Lee Han-soo  |  2019-02-11 11:23
라인
Samsung BioLogics posts ₩535.8 billion in 2018 sales
Samsung BioLogics said Thursday that it recorded 535.8 billion won ($479 mi...
by Lee Han-soo  |  2019-02-01 11:56
라인
Celltrion to export biosimilars to Latin America
Celltrion Healthcare said Thursday that it has successfully won bids to sup...
by Lee Han-soo  |  2019-01-31 11:12
라인
Samsung Bioepis’ biosimilar sales in EU exceed $500 million
Samsung Bioepis’ biosimilar sales in European Union surpassed $500 million ...
by Lee Han-soo  |  2019-01-30 18:17
라인
KIST finds boiling histotripsy’s mechanism to remove tumor tissue
Local researchers have found how a boiling histotripsy worked to get rid of...
by Cho In-sung  |  2019-01-24 11:30
라인
FDA OKs Samsung Bioepis’ first oncology medicine
Samsung Bioepis said Monday that the U.S. Food and Drug Administration has ...
by Lee Han-soo  |  2019-01-21 11:43
라인
Celltrion wins patent dispute on Truxima
Celltrion said Friday that it has won the domestic patent appeal for chroni...
by Lee Han-soo  |  2019-01-18 11:47
라인
Over 1,000 bio-ventures set up in past 3 years
Korea’s bio-venture business boom peaked in 2016 and turned downward, but a...
by Lee Han-soo  |  2019-01-17 22:05
라인
CL Bio wins patent for substance that improves antidiabetic functions
CL Bio, a local biopharmaceutical firm, said Monday that it has acquired al...
by Lee Han-soo  |  2019-01-14 12:34
여백
여백
여백
Back to Top